Rucaparib Camsylate
FDA-approved product (tablet, oral), marketed as Rubraca.
- Registered studies
- 7
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
- Ovarian cancer
- Ovarian carcinoma
- Ovarian neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Poly (adp-ribose) polymerase (parp) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
7registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Rucaparib Camsylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04455750 · start 2021-10-14
Registered record
- Registry ID
- NCT04455750
- Conditions
- Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Enzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate; Goserelin Acetate; Degarelix; Quality-of-Life Assessment; Questionnaire Administration
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2021-10-14
- Completion
- 2027-09
- Enrolment
- 61
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 moreInterventionEnzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate +4 morePhasePhase 3Registry statusActive not recruitingA Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
NCT04171700 · start 2020-01-16
Registered record
- Registry ID
- NCT04171700
- Conditions
- Solid Tumor
- Interventions
- Rucaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2020-01-16
- Completion
- 2022-07-15
- Enrolment
- 83
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSolid TumorInterventionRucaparibPhasePhase 2Registry statusTerminatedDocetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
NCT03442556 · start 2018-08-24
Registered record
- Registry ID
- NCT03442556
- Conditions
- ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Homologous Recombination Deficiency; Prostate Carcinoma Metastatic in the Bone; PSA Level Greater Than or Equal to Two; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Carboplatin; Docetaxel; Laboratory Biomarker Analysis; Rucaparib Camsylate; Rucaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2018-08-24
- Completion
- 2025-06-04
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Castration Levels of Testosterone +6 moreInterventionCarboplatin; Docetaxel; Laboratory Biomarker Analysis; Rucaparib Camsylate +1 morePhasePhase 2Registry statusTerminatedMirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03552471 · start 2018-07-12
Registered record
- Registry ID
- NCT03552471
- Conditions
- BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer
- Interventions
- Laboratory Biomarker Analysis; Mirvetuximab Soravtansine; Pharmacokinetic Study; Rucaparib Camsylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-07-12
- Completion
- 2022-12-19
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma +6 moreInterventionLaboratory Biomarker Analysis; Mirvetuximab Soravtansine; Pharmacokinetic Study; Rucaparib CamsylatePhasePhase 1Registry statusCompletedRucaparib Hepatic Impairment Study in Patients With a Solid Tumor
NCT03521037 · start 2018-02-27
Registered record
- Registry ID
- NCT03521037
- Conditions
- Neoplasms
- Interventions
- Rucaparib camsylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-02-27
- Completion
- 2021-02-24
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeoplasmsInterventionRucaparib camsylatePhasePhase 1Registry statusCompletedAbsorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
NCT02986100 · start 2016-11
Registered record
- Registry ID
- NCT02986100
- Conditions
- Solid Tumor
- Interventions
- C-14 labeled Rucaparib; Rucaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-11
- Completion
- 2018-09
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSolid TumorInterventionC-14 labeled Rucaparib; RucaparibPhasePhase 1Registry statusCompletedPharmacokinetic Drug-Drug Interaction Study of Rucaparib
NCT02740712 · start 2016-04
Registered record
- Registry ID
- NCT02740712
- Conditions
- Neoplasms
- Interventions
- Caffeine; Warfarin; Omeprazole; Midazolam; digoxin; Vitamin K; Rucaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-04
- Completion
- 2019-09
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeoplasmsInterventionCaffeine; Warfarin; Omeprazole; Midazolam +3 morePhasePhase 1Registry statusCompleted